2021 Walk4MD Wrap-Up
Thanks to the dedicated teams and participants who registered and fundraised for The Tenaquip Foundation Walk4MD, as well as the amazing donors, sponsors, and research champions, this year’s event was a huge success!
As of today, Muscular Dystrophy Canada (MDC) has exceeded their fundraising goal and reached a total of $925, 158.28 with donations still coming in! The funds raised will be instrumental to delivering MDC’s basket of programs and services, funding life-changing equipment and technologies, investing in translational and clinical research, supporting next-generation clinicians and scientists, increasing education and awareness, influencing positive change, providing emotional support to those affected by NMD… and more.
This year, MDC focused their signature Walk event on research – in addition to a selected Research Champions Team, over 100 clinicians, researchers and students participated. The feedback from our community on the enhanced focus on research has been so positive.
If you missed the virtual event on Saturday, you can watch the replay here:
French: https://youtu.be/-cTGtzfMoT8
English: https://youtu.be/CWrInr5yL5g
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.